Trial Profile
A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 16 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 13 Feb 2014 Planned End Date changed from 1 Mar 2016 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 14 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.